Ten years have passed since tryparsamide was given to Lorenz and his colleagues by the Rockefeller Institute to be tried clinically for patients suffering from various forms of syphilis. Six years have passed since it was put on the market for general use by Merck and Company. Ten years are sufficient for a survey of the value of a drug, for one can discuss both its immediate and continued results.
In a review of the literature, it was interesting to note how little has been written about tryparsamide in comparison to the vast amount written about malarial therapy, which was first tried in 1922. If the literature were any indication of the extent of its usage, I should feel that tryparsamide is still a relatively unknown drug.
A complete bibliography will be found at the end of this paper. On glancing over it, one realizes that in Europe tryparsamide
LICHTENSTEIN JV. TRYPARSAMIDE THERAPY: A FOLLOW-UP REPORT ON SEVENTY-SIX PATIENTS WITH NEUROSYPHILIS TREATED WITH TRYPARSAMIDE. Arch Derm Syphilol. 1931;24(2):182–195. doi:https://doi.org/10.1001/archderm.1931.01450010189002
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: